Ipsen announces 18 posters to be presented at the 15th Annual ENETS Conference

Paris (France), 6 March 2018 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced that
lanreotide (Somatuline®), cabozantinib (Cabometyx®), and telotristat ethyl (Xermelo®), alongside
research on real-world NET treatment, nuclear medicine and imaging, and the patient experience
will be highlighted in 18 posters at the 15th Annual ENETS (European Neuroendocrine Tumor
Society) Conference, to be held from March 7th to March 9th in Barcelona, Spain. The posters will be
presented during two poster sessions: March 8th from 15:20 pm to 16:05 pm (CET) and March 9th
from 10:40 am to 11:30 am (CET).

 

Ipsen remains committed to advancing research and education in order to better understand and
continuously improve treatment options for patients with neuroendocrine tumors (NETs). Our goal is to optimize the treatment outcomes and quality of life of patients with NETs. We are pleased to
present encouraging scientific and clinical data from our portofolio in neuroendocrine tumors and
carcinoid syndrome ” said Sotirios Stergiopoulos, MD, Senior Vice-President, Head of Global
Medical Affairs (GMA) and Chief Medical Officer (CMO), Ipsen.

The presentations upcoming on Cabometyx®, Xermelo®, Somatuline® and 68Ga-OPS-202 are
based on the results of investigational research studies.

 

Lanreotide (Somatuline®) is featured in 4 posters:

o Poster H19 – Category: Medical Treatment – Chemotherapy Somatostatin Analogues, Interferon
Title: Disease control in progressive pancreatic and intestinal neuroendocrine tumours by
combined treatment with lanreotide autogel and temozolomide: the SONNET study
Authors: M. Pavel, U.-F. Pape, M. Raderer, A. Rinke, D. Hörsch, H. Lahner, T. Denecke, A. Koch,
N. Liyanage, A. Raspel

o Poster J09 – Category: Medical Treatment – Others Not Specified
Title: Observational study of perception of information and quality of life in patients with
neuroendocrine tumor starting lanreotide – Study design
Authors: V. Hautefeuille, F. Bonnetain, D. Gueguen, A. Houchard, P. Hammel

o Poster – H14 Category: Medical Treatment – Chemotherapy Somatostatin Analogues, Interferon
Title: Somatostatin Analog (SSA) Usage in Neuroendocrine Tumors (NETs): A Retrospective
Database Analysis with Supplemental Chart Review
Authors: A.J. Klink, B. Feinberg, H.T. Yu, D. Ray, S. Pulgar, A. Phan, A. Vinik

o Poster – K01 – Category: Nuclear Medicine Imaging and Therapy (PRRT)
Title: Influence of Lanreotide on Uptake of [68Ga]-DOTATATE in Patients with NETs
Authors: E.A. Aalbersberg, B.J. de Wi – van der Veen, L.J. Saveur,G.D. Valk, M.E.T. Tesselaar,
M.P.M. Stokkel
Investigator-lead study

 

Cabozantinib (Cabometyx®) is featured in 1 poster:

o Poster I05 – Category: Medical Treatment – Targeted Therapies
Title: Phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine
tumors
Authors: J. A. Chan, J. E. Faris, J. E. Murphy, L. S. Blaszkowsky, N. J. McCleary, J. A.
Meyerhardt, T. A. Abrams, S. Zhang, A. Reardon, B. Fitzpatrick, M. H. Kulke, D. P. Ryan
Investigator-lead study

 

Telotristat (Xermelo®) is featured in 1 poster:

o Poster J06 Category: Medical Treatment – Others, Not Specified
TELESTAR/TELECAST time to sustained BM improvement – “[Lexicon-lead study]” – Telotristat
Title: Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl:
Analyses of Two Phase 3 Studies in Carcinoid Syndrome
Authors: J. S. Dillon, M. H. Kulke, D. Hörsch, L. B. Anthony, R. R. P. Warner, E. Bergsland,
S. Welin, T. M. O’Dorisio, P. L. Kunz, Chad McKee, P. Lapuerta, M. Pavel
Lexicon-lead study

 

68Ga-OPS202 is featured in 1 poster:

o Poster K25 – Category: Nuclear Medicine Imaging and Therapy (PRRT)
Title: Study to Evaluate the Optimal Dose of 68Ga-OPS202 as a PET Imaging Agent in Patients
with GEP -NET
Authors: I. Virgolini, A. Brouwers, A. Haug , H. Grønbæk, A. Kjær, D. Novac, A. Ang, C. Miller,
J. Kaufmann, J. Czernin

 

6 posters present Real World Data:

o Poster D53 – Category: Epidemiology/Natural History/Prognosis – Registries, Nationwide and
Regional Surveys
Title: Prevalence of Carcinoid Syndrome in the European Union: Systematic Review
Authors : G. Nayroles, A. Bergamasco, J. Mouchet, Y. Moride

o Poster J05 – Category: Medical Treatment
Title: On-going Evaluation of the Use of Resources and the Costs (UR/C) Associated with
Controlled or Uncontrolled Carcinoid Syndrome (CS) in Patients (pts) with Neuroendocrine
Tumours (NETs). RECOSY Study
Authors : A. Custodio, A. Carmona-Bayonas, C. Villabona, M. Pérez, G. de la Cruz, P. Jiménez-
Fonseca

 

o Poster D05 – Category: Medical Treatment – Epidemiology Natural History/Prognosis – Registries,

Nationwide and Regional Surveys
Title: Direct cost of metastatic gastroenteropancreatic neuroendocrine tumours (GEP-NET)
Grade 1 or 2 (G1/G2) in relation to time since diagnosis shows growing importance of
somatostatin analogues (SSA)
Authors : D. Granfeldt, Å. Björstad, T. Marlow, J. Dinet, P. Myrenfors, E. Lesén, I. Björholt, A-K. Elf,
V. Johanson

o Poster D06 – Category: Epidemiology/Natural History/Prognosis – Registries, Nationwide and
Regional Surveys
Title: Long-acting Somatostatin Analogue (LA-SSA) Treatment Durations in Patients Diagnosed
with Metastatic Gastroenteropancreatic Neuroendocrine Tumours (GEP-NET) Grade 1 or 2
(G1/G2) in Sweden
Authors: D. Granfeldt, Å. Björstad, T. Marlow, J. Dinet, P.Myrenfors, E. Lesén, I. Björholt, A-K.
Elf, V. Johanson

o Poster D77 Category: Epidemiology/Natural History/Prognosis – Registries, Nationwide and
Regional Surveys
Title: Long-acting Somatostatin Analogue (LA-SSA) Treatment Patterns in Patients Diagnosed
with Metastatic Gastroenteropancreatic Neuroendocrine Tumours (GEP-NET) Grade 1 or 2
(G1/G2) in Sweden
Authors: Å. Björstad, D. Granfeldt, T. Marlow, J. Dinet, P. Myrenfors, E. Lesén, I. Björholt, A-K.
Elf, V. Johanson

 

o Poster H09 – Category: Medical Treatment – Chemotherapy Somatostayin Analogues, Interferon

Title: Therapeutic sequences in patients with G1-G2 neuroendocrine tumors (NETs): an
observational, multicentre, prospective/retrospective study
Authors: A.A. Faggiano, S.A. Di Maio, S.B Tafuto, C.C Mocerino, A.D Di Sarno, G.E Palmieri,
I.F Puliafito, I.G De Luca, V.H Guarnotta, S.I Leo, L.J Tozzi, A.A Colao
Investigator-lead study

 

2 posters present data on NET and carcinoid syndrome:

o Poster J13 – Category: Medical Treatment, Others Not Specified
Title: Patient and Clinician Perspectives on Symptom Priorities across the Spectrum of
Neuroendocrine Tumors (NETs)
Authors: K.A. Kaiser, K.A. Webster, S. Shaunfield, G.J. Greene, S.E. Yount, L. Lacson, A.B.
Benson III, D.M. Halperin, M. Feuilly, F. Marteau, and D. Cella
Investigator-lead study

 

o Poster D20 – Category: Epidemiology/Natural History/Prognosis – Registries, Nationwide and
Regional Surveys
Title: Carcinoid syndrome open questions – Evaluations from a real life setting
Authors: R. Fijalkowski, A. Singh, R. Baum, H. Kulkarni, K. Niepsch, D. Kaemmerer, M.
Hommann, D. Hoersch
Investigator-lead study

 

Patient experience and quality of life is featured in 2 posters:

o Poster D59 – Category: Epidemiology/Natural History/Prognosis – Registries, Nationwide and
Regional Surveys
Title: Patient survey devoted to characterizing experience and expectations of patients with
Neuroendocrine Tumors (NET)
Authors: M. Sarabi, D. Gueguen, E. Baudin

o Poster J08 – Category: Medical treatment, Others Not Specified
Title: Clinical Utility (CU) Evaluation of the Health-Related Quality-Of-Life (HRQoL) QLQGINET21
Questionnaire (QNR) in the Treatment of Patients (pts) with Gastrointestinal (GI)
Neuroendocrine Tumours (NETs). QUALINETS Study
Authors: J. Gallego, O. Reig, J. Sastre, I. García, A. Segura, J. Capdevila, A. Carmona, I.
Sevilla, T. Alonso, G. Crespo, L. García, D. Arnau, G. de la Cruz, M. Benavent

 

Predicting response to SSAs:

o Poster F08 – Category: Biomarkers
Title: Plasma Protein hK14 Strongly Predict Pronounced Chromogranin A Response in Small
Intestinal Neuroendocrine Tumor Patients After Somatostatin Analog Treatment: The Nordic
EXPLAIN Biomarker Study
Authors: M. Kjellman, U.Knigge, S.Welin, H.Gronbaek, E.This-Evensen, H.Sorbye, MT
Jørgensen, V. Johansson, S. Metso, K.Becker, T. Ström, P.Myrenfors, R. Belusa and The
Nordic NET Biomarker Group

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved. - 2019